Just went down a rabbit hole looking at some biotech penny stocks that actually have decent analyst backing. Most of these plays are risky as hell, but a few caught my eye because they're not complete lottery tickets.

So like, the ones worth watching seem to be in T-cell therapy and RNA medicines. Adicet Bio is doing gamma delta T-cell work for cancer and autoimmune stuff - market cap under $200M and analysts are calling it a strong buy with like 340% upside. Stoke Therapeutics is working on RNA-based treatments for rare diseases like Dravet syndrome. They've got a crazy 86X cash-to-debt ratio which is honestly wild for a biotech penny stocks company.

Then there's Actinium Pharmaceuticals doing targeted radiotherapy for cancer patients who've failed other treatments. The radiation oncology market is supposed to grow from $8.2B to like $19B by 2032, so the tailwind could be real. Clearside Biomedical has FDA approval for something novel in retinal disease treatment - first of its kind delivery method into the eye. Karyopharm is pushing this SINE technology for various cancers and has solid revenue growth despite the stock getting hammered.

Outlook and Cara are the more speculative plays. Outlook's working on vision preservation therapies and Cara is tackling pruritus treatment - sounds niche but apparently there's huge unmet need. Both have unanimous strong buy ratings.

Obviously these biotech penny stocks can crater fast. The whole sector has insane volatility and most of these companies could fail. But if you're looking for plays with actual clinical progress and not just hype, these at least have analyst consensus behind them. Still wouldn't throw money at them without serious research first though.